



DRW
\$

AMENDMENT TRANSMITTAL LETTER (Small Entity)					Docket No. A-8636	
Applicant(s): George M. Halow						
Application No. 10/748,185	Filing Date December 31, 2003	Examiner Amy A. Lewis	Customer No. 20741	Group Art Unit 1614	Confirmation No. 5571	
Invention: COMPOSITION AND METHOD FOR TREATMENT OF HEPATIC ENCEPHALOPATHY						
 COMMISSIONER FOR PATENTS:						
Transmitted herewith is an amendment in the above-identified application.						
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27						
The fee has been calculated and is transmitted as shown below.						
CLAIMS AS AMENDED						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	32 -	25 =	7	x \$25.00	\$175.00	
INDEP. CLAIMS	3 -	3 =	0	x \$100.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$175.00	
<input type="checkbox"/> No additional fee is required for amendment.						
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____						
<input checked="" type="checkbox"/> A check in the amount of \$175.00 to cover the filing fee is enclosed.						
<input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 08-2455						
<input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.						
<input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.						
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.						
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
<div style="display:flex; justify-content:space-between;"><div style="width:45%;"> Signature Jean A. Buttm - Reg. 24,236 Hoffman, Wasson & Gitler, P.C. 2461 South Clark Street Crystal Center 2 - Suite 522 Arlington, VA 22202 703.415.0100</div><div style="width:45%; text-align:right;">Dated: <i>1 November 2005</i></div></div>						
<div style="display:flex; justify-content:space-between;"><div style="width:45%;">CC:</div><div style="width:45%; border:1px solid black; padding:5px;"><div>I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____ (Date)</div><div>_____ Signature of Person Mailing Correspondence</div><div>_____ Typed or Printed Name of Person Mailing Correspondence</div></div></div>						



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

George M. HALOW

Group Art Unit: **1614**

Serial No: **10/748,185**

Examiner: **Amy A. Lewis**

Filed : **December 31, 2003**

For : **COMPOSITION AND METHOD FOR TREATMENT
OF HEPATIC ENCEPHALOPATHY**

AMENDMENT UNDER 35 USC §115

11/02/2005 HBEYENE1 00000045 10748185

01 FC:2202

175.00 0P

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Examiner has rejected Claims 15-25 under 35 USC §112, second paragraph, referring to the claim structure. The phrase "method or composition" in these claims was a drafting error and has been modified to correspond to the relevant dependencies of each claim. Withdrawal of this rejection is accordingly requested.

The Examiner has further rejected Claims 1 and 2 under 35 USC §102(b) over Roblin et al. Gastroenterol Clin Biol 18:1146 (1994). The Examiner cites only the title of the article, "Use of polyethylene glycol 4000 in hepatic encephalopathy related to digestive hemorrhages", as grounds for the rejection, although a copy of the article itself (presumably translated from the French) was provided to Applicant.

The full article describes a method for treatment of ruptured esophageal varicose veins associated with portal hypertension in a cirrhosis patient with hepatic encephalopathy (HE), comprising the administration of 2 liters of a PEG 4000 (Fortrans 7) via a gastric probe over two hours to evacuate intestinal blood resulting from acute digestive hemorrhage. (Fortrans is an isotonic colonic lavage solution which contains PEG 4000 and electrolyte, see attached printout (<http://www.emergingp.com/main/fortrans.asp>) of Emerging Pharma website; typically, such PEG lavage solutions contain from about